232 related articles for article (PubMed ID: 37428793)
1. Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis.
Alwan SN; Taylor AB; Rhodes J; Tidwell M; McHardy SF; LoVerde PT
PLoS Pathog; 2023 Jul; 19(7):e1011018. PubMed ID: 37428793
[TBL] [Abstract][Full Text] [Related]
2. An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans.
Guzman MA; Rugel AR; Tarpley RS; Alwan SN; Chevalier FD; Kovalskyy DP; Cao X; Holloway SP; Anderson TJC; Taylor AB; McHardy SF; LoVerde PT
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008517. PubMed ID: 32810153
[TBL] [Abstract][Full Text] [Related]
3. Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
da Silva VBR; Campos BRKL; de Oliveira JF; Decout JL; do Carmo Alves de Lima M
Bioorg Med Chem; 2017 Jul; 25(13):3259-3277. PubMed ID: 28495384
[TBL] [Abstract][Full Text] [Related]
4. Schistosome Sulfotransferases: Mode of Action, Expression and Localization.
Guzman MA; Rugel A; Alwan SN; Tarpley R; Taylor AB; Chevalier FD; Wendt GR; Collins JJ; Anderson TJC; McHardy SF; LoVerde PT
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890311
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of oxamniquine, praziquantel and a combination of both drugs on the intramolluscan phase of Schistosoma mansoni.
Mattos AC; Pereira GC; Jannotti-Passos LK; Kusel JR; Coelho PM
Acta Trop; 2007 May; 102(2):84-91. PubMed ID: 17498638
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for hycanthone drug action in schistosome parasites.
Guzman M; Rugel A; Tarpley RS; Cao X; McHardy SF; LoVerde PT; Taylor AB
Mol Biochem Parasitol; 2020 Mar; 236():111257. PubMed ID: 32027942
[TBL] [Abstract][Full Text] [Related]
7. Ferrocenyl, Ruthenocenyl, and Benzyl Oxamniquine Derivatives with Cross-Species Activity against Schistosoma mansoni and Schistosoma haematobium.
Hess J; Panic G; Patra M; Mastrobuoni L; Spingler B; Roy S; Keiser J; Gasser G
ACS Infect Dis; 2017 Sep; 3(9):645-652. PubMed ID: 28686009
[TBL] [Abstract][Full Text] [Related]
8. Schistosomiasis: Drugs used and treatment strategies.
Siqueira LDP; Fontes DAF; Aguilera CSB; Timóteo TRR; Ângelos MA; Silva LCPBB; de Melo CG; Rolim LA; da Silva RMF; Neto PJR
Acta Trop; 2017 Dec; 176():179-187. PubMed ID: 28803725
[TBL] [Abstract][Full Text] [Related]
9. Rational approach to drug discovery for human schistosomiasis.
LoVerde PT; Alwan SN; Taylor AB; Rhodes J; Chevalier FD; Anderson TJ; McHardy SF
Int J Parasitol Drugs Drug Resist; 2021 Aug; 16():140-147. PubMed ID: 34111649
[TBL] [Abstract][Full Text] [Related]
10. Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?
Rugel AR; Guzman MA; Taylor AB; Chevalier FD; Tarpley RS; McHardy SF; Cao X; Holloway SP; Anderson TJC; Hart PJ; LoVerde PT
Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():8-15. PubMed ID: 32315953
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tegumental damage to Schistosoma mansoni and S. haematobium after in vitro exposure to ferrocenyl, ruthenocenyl and benzyl derivatives of oxamniquine using scanning electron microscopy.
Buchter V; Hess J; Gasser G; Keiser J
Parasit Vectors; 2018 Nov; 11(1):580. PubMed ID: 30400935
[TBL] [Abstract][Full Text] [Related]
12. Altered response of strain of Schistosoma mansoni to oxamniquine and praziquantel.
Bonesso-Sabadini PI; de Souza Dias LC
Mem Inst Oswaldo Cruz; 2002 Apr; 97(3):381-5. PubMed ID: 12048569
[TBL] [Abstract][Full Text] [Related]
13. In vivo efficiency of praziquantel treatment of single-sex Schistosoma japonicum aged three months old in mice.
Wang N; Peng HQ; Gao CZ; Cheng YH; Sun MT; Qu GL; Webster JP; Lu DB
Int J Parasitol Drugs Drug Resist; 2022 Dec; 20():129-134. PubMed ID: 36403362
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.
Bustinduy AL; Waterhouse D; de Sousa-Figueiredo JC; Roberts SA; Atuhaire A; Van Dam GJ; Corstjens PL; Scott JT; Stanton MC; Kabatereine NB; Ward S; Hope WW; Stothard JR
mBio; 2016 Aug; 7(4):. PubMed ID: 27507822
[TBL] [Abstract][Full Text] [Related]
15. MCR synthesis of praziquantel derivatives.
Liu H; William S; Herdtweck E; Botros S; Dömling A
Chem Biol Drug Des; 2012 Apr; 79(4):470-7. PubMed ID: 22151001
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium.
Kovač J; Vargas M; Keiser J
Parasit Vectors; 2017 Aug; 10(1):365. PubMed ID: 28764732
[TBL] [Abstract][Full Text] [Related]
17. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific.
Fallon PG; Doenhoff MJ
Am J Trop Med Hyg; 1994 Jul; 51(1):83-8. PubMed ID: 8059919
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger.
Garba A; Lamine MS; Barkiré N; Djibo A; Sofo B; Gouvras AN; Labbo R; Sebangou H; Webster JP; Fenwick A; Utzinger J
Acta Trop; 2013 Nov; 128(2):334-44. PubMed ID: 22940014
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni.
Mohammad OS; Hussein HM; Abdel-Sayed SW; Mohamed GA; Shehata MAS
Parasitol Res; 2024 May; 123(5):215. PubMed ID: 38771511
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of praziquantel and reinfection patterns in single and mixed infection foci for intestinal and urogenital schistosomiasis in Cameroon.
Tchuem Tchuenté LA; Momo SC; Stothard JR; Rollinson D
Acta Trop; 2013 Nov; 128(2):275-83. PubMed ID: 23791803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
